MedicineAll countries · Checked
Eloralintide and Amycretin: New Amylin Weight Loss Drugs in Trials
Eloralintide (Eli Lilly) and amycretin (Novo Nordisk, also called zenagamtide) are once-weekly injections that act on the amylin receptor. Both are still in clinical trials. In a 48-week Phase 2 trial, eloralintide cut average body weight by up to 20%, and amycretin cut it by up to 14.6% in a 36-week Phase 2 trial.
The two drugs at a glance
Both are experimental, so there is no product to ask a doctor for. Today they are used only inside clinical trials.
Eloralintide (Eli Lilly)Amylin agonist, Phase 3
Amycretin / zenagamtide (Novo Nordisk)GLP-1 and amylin agonist, Phase 3
Best average weight lossAbout 20% (eloralintide), 14.6% (amycretin)
The two trials had different people and lengths, so the numbers cannot be compared head to head.
Want the cost of the GLP-1 medicines you can use today?
Compare GLP-1 medicine prices by countryOther drugs in development are tracked in new GLP-1 drugs.
EloralintideResultsSide effectsEloraTZPPhase 3AmycretinAmycretin resultsAmycretin Phase 3ComparePriceFAQ
What is eloralintide?
Eloralintide is a once-weekly injection under the skin from Eli Lilly. It switches on the amylin receptor and nothing else. Its development code is LY3841136.
Wegovy and Mounjaro work through GLP-1 receptors. Eloralintide uses a different target, which makes it a new class of weight loss medicine. The current GLP-1 drugs are explained in GLP-1 drugs explained.
No approved dose or price exists yet, so there is no dosing chart. Doses in the trials differ from study to study.
Eloralintide weight loss results
The 48-week Phase 2 trial enrolled 263 US adults without diabetes. People received a weekly injection of 1 mg to 9 mg, or placebo.
1 mg−9%3 mg−12%9 mg−20%
Placebo lost 0.4% on average. The 6 mg dose reached −18%.
These are averages from the efficacy analysis, which counts people as if they stayed on treatment. They are not a promise for any one person.
Eloralintide side effects
The most common side effects were nausea and fatigue. At 9 mg, nausea affected 33% of people, against 14% on placebo.
Fatigue affected 43% on 9 mg and 12% on placebo. At 1 mg, nausea was 11% and fatigue 0%.
Each arm had only 24 to 54 people, so the rates will firm up in Phase 3.
EloraTZP: eloralintide plus tirzepatide
Lilly is also testing eloralintide together with tirzepatide, the medicine in Mounjaro and Zepbound. The combination is called EloraTZP.
The Phase 2b results were released on September 30, 2026, at the EASD meeting. They covered 367 adults with obesity or overweight and type 2 diabetes, who used two separate pens for 48 weeks.
Average weight change at 48 weeks
Eloralintide 9 mg + tirzepatide 15 mg−23.3%
Eloralintide 6 mg + tirzepatide 10 mg−19.9%
Tirzepatide 15 mg alone−14.8%
Eloralintide 9 mg alone−11.1%
Placebo−3.0%
The top combination lost 8.5 percentage points more than tirzepatide 15 mg alone. HbA1c, the blood sugar measure, also fell further: −2.9% against −2.4%.
This is company-funded data presented at a conference. Phase 3 has to confirm it.
Eloralintide Phase 3 trials
ClinicalTrials.gov lists several recruiting Phase 3 trials. The two largest on weight loss are 1,980 adults with obesity and no diabetes, and 1,035 adults with obesity and type 2 diabetes.
Others test sleep apnea (800 people), knee osteoarthritis pain (900) and people who stay obese on a weekly incretin drug (900).
For EloraTZP, a 1,000-person Phase 3 trial in type 2 diabetes started on October 16, 2026. A 2,115-person trial in people without diabetes is listed to start in December 2026.
The earliest listed primary completion date is January 2028. Approval and prescribing would come after that.
What is amycretin (zenagamtide)?
Amycretin is Novo Nordisk's drug, also named zenagamtide. One molecule acts on both GLP-1 and amylin receptors.
It is being tested as a weekly injection and as a tablet. The tablet Phase 3 trial, AMAZE 9, plans to enroll 950 people and is recruiting.
Amycretin trial results
Phase 2 results came out on June 6, 2026, at the ADA meeting. They covered 262 adults with type 2 diabetes not well controlled on metformin, who injected weekly for 36 weeks. This was a diabetes trial, not a weight loss trial.
10 mg−12.9%20 mg−13.1%40 mg−14.6%
Placebo lost 2.1%. The lower doses lost 4.4% (0.4 mg), 7.6% (1.5 mg) and 8.2% (5 mg).
At 40 mg, HbA1c fell by 1.71 percentage points, against 0.14 on placebo, from a starting level of 7.8%.
Amycretin Phase 3 trials
For weight loss, a 650-person trial against semaglutide started on September 22, 2026, and the tablet trial AMAZE 9 started on August 31, 2026. AMAZE 13 is listed to test 400 people in Asia from January 2027.
A trial in 8,500 adults with cardiovascular disease and overweight or obesity is listed to start on October 26, 2026, and is not yet recruiting.
Several type 2 diabetes trials are also listed, including AMBITION 7 against insulin glargine, with 1,778 people.
None of the Phase 3 trials listed so far is due to finish before June 2028.
Eloralintide vs amycretin
Eloralintide targets amylin only. Amycretin targets GLP-1 and amylin together. They come from rival companies, Lilly and Novo Nordisk.
Their weight results cannot be lined up directly. Eloralintide's came from people without diabetes over 48 weeks, and amycretin's from people with diabetes over 36 weeks.
Other drugs in late development are covered in survodutide, CagriSema and retatrutide.
Eloralintide price and release date
Neither drug has a price, because neither is approved. There is no release date until the Phase 3 trials report.
To weigh the medicines you can get today, use the GLP-1 cost calculator or see Mounjaro price by country.
Eloralintide and amycretin FAQ
Is eloralintide approved?
No. It is in Phase 3 trials, and the earliest listed primary completion is January 2028.
Does eloralintide work better than Wegovy or Mounjaro?
Not known yet. The combination EloraTZP beat tirzepatide 15 mg (−23.3% against −14.8%), but eloralintide 9 mg alone reached −11.1% in that diabetes trial, below tirzepatide 15 mg.
Are amycretin and zenagamtide the same drug?
Yes. Novo Nordisk names zenagamtide as also known as amycretin.
Is amycretin a pill?
A tablet is in testing too. The Phase 3 trial AMAZE 9 uses tablets and is recruiting.
Can I join a trial?
Recruiting trials are listed on ClinicalTrials.gov under each drug name. Entry rules differ by trial.
Keep reading
New GLP-1 drugs in development
Retatrutide: trial results and timeline
Survodutide: trial results and timeline
CagriSema: trial results and FDA decision
Mounjaro (tirzepatide) by country
This page follows trial registries, journal papers and company releases and is updated when new results appear. See how we check our pages.
Update log
: First published.
Sources
The Lancet, Eloralintide, a selective amylin receptor agonist: a 48-week phase 2 trial.
EASD, EloraTZP Phase 2b results (September 30, 2026).
Novo Nordisk, Zenagamtide (amycretin) Phase 2 results in type 2 diabetes (June 6, 2026).
ClinicalTrials.gov, eloralintide studies and zenagamtide studies.
GLP1 Note is an independent information site. Joining a trial or choosing a medicine is a decision for you and your prescriber.